Vera Therapeutics, Inc. (VERA): Price and Financial Metrics
GET POWR RATINGS... FREE!
VERA Stock Price Chart Interactive Chart >
VERA Price/Volume Stats
|Current price||$8.74||52-week high||$24.98|
|Prev. close||$9.14||52-week low||$5.20|
|Day high||$9.51||Avg. volume||1,522,483|
|50-day MA||$14.20||Dividend yield||N/A|
|200-day MA||$17.03||Market Cap||241.73M|
Vera Therapeutics, Inc. (VERA) Company Bio
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Most Popular Stories View All
VERA Latest News Stream
|Loading, please wait...|
VERA Latest Social Stream
View Full VERA Social Stream
Latest VERA News From Around the Web
Below are the latest news stories about VERA THERAPEUTICS INC that investors may wish to consider to help them evaluate VERA as an investment opportunity.
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Jonathan Barratt, PhD, FRCP, from the University of Leicester, who, together with Vera Therapeutics management, will provide an update on atacicept’s ORIGIN Phase 2b data
If you are able to digest the risk that comes with pursuing oversized gains this year, look into the following three crypto winners.
Shares of the developmental-stage immunology company Vera Therapeutics (NASDAQ: VERA) gained a stately 49% this week, according to data provided by S&P Global Market Intelligence. What sparked this abrupt run-up in Vera's shares? While a pooled analysis of the drug's 75/150 mg doses yielded a statistically significant 31% mean reduction in protein in the urine (proteinuria) at week 24, Wall Street wasn't convinced this efficacy result would be competitive against other therapies in development for Berger's disease.
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
VERA Price Returns